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ABSTRACT
Objectives Determine whether an ultrathin biodegradable 
polymer sirolimus- eluting stent (‘Orsiro’—BP- SES) has 
clinical benefits over second- generation durable polymer 
drug- eluting stents (DP- DES).
Methods We conducted a prospective systematic review 
and meta- analysis of randomised clinical trials comparing 
Orsiro BP- SES against DP- DES (PROSPERO Registration: 
CRD42019147136). The primary outcome was target 
lesion failure (TLF): composite of cardiac death, target 
vessel myocardial infarction (TVMI) and clinically indicated 
target lesion revascularisation (TLR)) evaluated at the 
longest available follow- up.
Results Nine trials randomised 11 302 patients to either 
Orsiro BP- SES or DP- DES. At mean weighted follow- up 
of 2.8 years, the primary outcome (TLF) occurred in 
501 of 6089 (8.2%) participants with BP- SES compared 
with 495 of 5213 (9.5%) participants with DP- DES. This 
equates to an absolute risk reduction of 1.3% in TLF in 
favour of Orsiro BP- SES (OR 0.82; 95% CI 0.69 to 0.98; 
p=0.03). This was driven by a reduction in TVMI (OR 0.80; 
95% CI 0.65 to 0.98; p=0.03). There were no significant 
differences in other clinical endpoints: cardiac death, TLR 
and stent thrombosis.
Conclusion The Orsiro BP- SES shows promising clinical 
outcomes in patients undergoing percutaneous coronary 
intervention compared with contemporary second- 
generation DES at a short to medium term follow- up. More 
research is warranted to evaluate performance over a 
longer follow- up period and in different clinical and lesion 
subsets.
INTRODUCTION
Contemporary second- generation durable 
polymer drug- eluting stents (DP- DES) have 
proven safety resulting in excellent clinical 
outcomes following percutaneous coronary 
intervention (PCI).1 2 Historical concerns 
from first- generation DES regarding the 
effects of durable polymer on delayed vessel 
healing and peristrut inflammation drove 
stent iterations incorporating biodegradable 
polymer sirolimus- eluting stents (BP- SES) 
with thinner struts.3 4 Indeed, thinner stent 
strut designs have recently been shown to 
reduce in- stent restenosis and target lesion 
revascularisation (TLR) in a pooled meta- 
analysis.5
The Orsiro BP- SES (BIOTRONIK, 
Buelach, Switzerland) has gained significant 
traction as one such ultrathin strut (60 µm in 
stents <3.0 mm diameter) sirolimus- eluting 
stent with a large clinical evidence base in 
contemporary studies.4 6–8 Many studies have 
shown non- inferiority of the Orsiro when 
compared with DP- DES, however, recent data 
from BIOFLOW V and BIOSTEMI studies 
support lower target lesion failure (TLF) in 
patients randomised to the Orsiro BP- SES 
over DP- DES.9 10 In light of the evolving 
evidence base, we performed a prospective 
meta- analysis of randomised controlled trials 
(RCTs) comparing Orsiro BP- SES versus 
DP- DES.
Key questions
What is already known about this subject?
 ► Recent randomised trials support non- inferiority 
of Orsiro ultrathin- strut biodegradable polymer 
sirolimus- eluting stent (BP- SES) compared with 
contemporary durable polymer drug- eluting stents 
(DP- DES).
What does this study add?
 ► Patients randomised to percutaneous coronary in-
tervention with Orsiro ultrathin- strut BP- SES had 
almost one- fifth less target lesion failure compared 
with contemporary DP- DES at mean follow- up of 
2.8 years. This was largely due to a significant re-
duction in target vessel myocardial infarction. There 
were no differences in other clinical and safety end-
points between the two group: cardiac death, target 
lesion revascularisation and stent thrombosis.
How might this impact on clinical practice?
 ► Ultrathin- strut BP- SES designs may further improve 
clinical outcomes over contemporary second- 
generation durable polymer DES. Future research is 
warranted with more randomised trials powered to 
compare modern generation stent platforms focus-
ing on utility in different patient subgroups.
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METHODS
The data, analytical methods and study materials 
have been made available to other researchers for the 
purposes of reproducing the results or replicating 
the procedure. The full study protocol was registered 
with the International Database of Prospectively Regis-
tered Systematic Reviews in Health and Social care 
(PROSPERO—CRD42019147136) and data is made avail-
able within this manuscript. This study was performed 
according to the Preferred Reporting Items for System-
atic reviews and Meta- Analyses guidelines.11 Patients or 
the public were not involved in the design, conduct, 
reporting or dissemination plans of our research.
Eligibility criteria
The inclusion criteria for the studies in our meta- analysis 
were as follows: RCTs comparing the Orsiro ultrathin 
strut, biodegradable polymer, sirolimus- eluting stents 
versus durable polymer second- generation drug- eluting 
stents, irrespective of the specific antiproliferative drug, 
with the availability of clinical or angiographic follow- up. 
Data on TLF had to be available in the publication or 
authors were approached for this data. Publications 
were excluded if they only compared two biodegradable 
polymer stents to each other and, for the biodegradable 
arm, were non- sirolimus eluting or had a strut other 
than an ultrathin strut. To minimise heterogeneity, we 
included only the studies that used the Orsiro BP- SES. 
Non- randomised trials, publications not in English and 
those with outcomes of interest less than 12 months 
follow- up were excluded.
Quality assessment
Two reviewers (CFS and MP) independently performed 
the risk- of- bias assessment of the included trials using the 
Cochrane Collaboration framework: bias arising from 
the randomisation process, bias due to deviation from 
intended intervention, bias due to missing outcome 
data, bias in measurement of the outcome and bias in 
selection of the reported results. Discrepancies were 
resolved by consensus with a third independent reviewer 
(TF). The risk- of- bias summary according to the risk- of- 
bias tool of the Cochrane collaboration framework is 
provided (figure 1). We planned to assess publication 
bias according to funnel plot asymmetry using standard 
error as the measure of study size and OR of treatment 
effect if we yielded over 10 studies.12
Search strategy
A systematic search of online databases of PubMed, 
EMBASE and Cochrane Central Register of Controlled 
Trials was performed until 26 August 2020. Peer- reviewed 
RCTs were selected using combinations of keywords, and 
their variations, pertinent to our intervention of interest 
and comparison with ‘biodegradable polymer’, ‘drug- 
eluting stent’, ‘sirolimus’, ‘orsiro’, ‘durable polymer’, 
‘everolimus’ and ‘zotarolimus’. Two reviewers (MRM and 
CFS) independently screened abstracts against the inclu-
sion and exclusion criteria while reference lists of rele-
vant articles and previous meta- analyses were reviewed to 
identify other relevant studies. They then screened the 
full text of potentially relevant trials. Disagreements were 
resolved by consensus involving a third reviewer (PB). 
Conference abstracts from major cardiology scientific 
sessions were searched for completeness.
Figure 1 Risk- of- bias summary for trials included in the 
meta- analysis.
Figure 2 PRISMA flow chart for studies included in the 
meta- analysis. BP- EES, biodegradable polymer everolimus- 
eluting stent; DP- DES, durable polymer drug- eluting stents; 
PRISMA, Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses; RCT, randomised controlled trial; SES, 
sirolimus- eluting stent.
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Outcomes and definitions
The primary outcome was TLF. TLF was defined as a 
composite index of cardiac death, target vessel myocar-
dial infarction (TVMI) and clinically indicated TLR. 
Secondary outcomes included cardiac death, TVMI, 
clinically indicated TLR and definite or probable stent 
thrombosis (ST). Definite or probable ST was deter-
mined according to the academic research consortium 
definition.13 Outcomes data were extracted by two inde-
pendent authors (MRM and RS). Differences in opinion 
were resolved by consensus involving a third reviewer 
(TF).
Data and statistical analysis
Follow- up duration was calculated as mean weighted dura-
tion according to study size. Pooled mean data were used 
to compare procedural aspects between the groups using 
an unpaired t- test. The study hypothesis was prespecified 
and tested with a two- tailed alpha of 0.05.
The statistical analysis was performed using R V 4.0 
using the metaphor package14 and RevMan V 5.3.5 (the 
Cochrane Collaboration). Analyses for all outcomes 
were done on an intention- to- treat basis. The random- 
effects method was selected on account of inherent 
heterogeneity related to the different types of stents and 
patient or lesion types enrolled. We also performed a 
fixed- effect (Mantel- Haenszel) approach for complete-
ness. We summarised the estimate of effect incorpo-
rating the clinical outcomes as OR with 95% CIs for 
our dichotomous data. Prespecified meta- regression 
was performed to assess the interaction between acute 
coronary syndrome (ACS) presentation and the primary 
endpoint. A leave- one- out sensitivity analysis was 
performed by iteratively removing one study at a time to 
assess whether any single study was driving our findings. 
Heterogeneity testing with Higgins I2 was performed 
with a threshold of >50% taken as evidence of signifi-
cant heterogeneity between studies.15 To assess the risk 
of type I and II errors, we conducted a trial sequential 
analysis (TSA) to calculate the required information 
size which is a summation of sample sizes from a given 
number of included trials, 5% overall type I error and 
power of 80%.16
RESULTS
Study selection and characteristics
An initial search yielded 332 citations. Applying inclusion 
criteria defined in the methods, we evaluated 45 abstracts 
of which we assessed 26 full- text publications with the 
longest available follow- up. The search flow diagram can 
be found in figure 2. Nine randomised trials met the 
inclusion criteria and reported primary outcome of TLF 
follow- up of 12 months or greater.10 17–26
All trials included were published between 2017 to 
2020. Nine trials randomised 11 302 patients to either 
Orsiro BP- SES or DP- DES. The mean weighted follow- up 
for the included studies was 2.8±1.4 years (table 1). The 
DP- DES included everolimus- eluting stents (6 trials) 
and zotarolimus- eluting stents (3 trials). A total of 6089 
patients were randomised to BP- SES strategy and 5213 
patients to the DP- DES strategy. The mean age of the 
population was 64.2±1.0 years with baseline patient char-
acteristics shown in table 2. Risk- of- bias and quality of 
evidence assessment is summarised in figure 1.
Efficacy outcome: TLF
There was a statistically significant reduction in the 
primary outcome (TLF) among patients randomised 
to Orsiro BP- SES (501/6089 (8.2%)) compared with 
DP- DES (495/5213 (9.5%); OR 0.82; 95% CI 0.69 to 0.98; 
p=0.037). The outcomes from the analysis are summa-
rised in table 3 and figure 3. Forrest plots are summarised 
in figure 4. Our findings remained significant using the 
Mantel- Haenszel fixed effects model (OR 0.86; 95% CI 
0.75 to 0.98, p=0.02). The key findings of the study are 
provided in a visual summary (figure 5.
Table 1 Baseline characteristics of included trials
Study Year N
Duration 
(years)
BP- SES DP- DES
Stent N Stent N
Bio- Resort 2019 2342 3 Orsiro 1169 Resolute Integrity (ZES) 1173
BIOSTEMI 2019 1300 1 Orsiro 649 XIENCE (EES) 651
BIOFLOW IV 2019 575 1 Orsiro 385 XIENCE (EES) 190
BIOFLOW V 2020 1334 3 Orsiro 884 XIENCE (EES) 450
BIOFLOW VI 2020 440 1 Orsiro 220 XIENCE (EES) 220
BIONYX 2020 2488 2 Orsiro 1245 Resolute Onyx (ZES) 1243
BIOSCIENCE 2018 2119 5 Orsiro 1063 XIENCE (EES) 1056
BIOFLOW II 2018 452 5 Orsiro 298 XIENCE (EES) 154
ORIENT 2019 372 3 Orsiro 250 Resolute Integrity (ZES) 122
PRISON IV 2017 330 1 Orsiro 165 XIENCE (EES) 165
BP- SES, biodegradable polymer sirolimus- eluting stent; DP- DES, durable polymer drug- eluting stents; EES, everolimus- eluting stents; 
ZES, zotarolimus- eluting stents.
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Safety endpoints: TVMI, cardiac death, TLR and ST
Safety endpoints were reported in all studies. TVMI 
occurred in 201 of 5832 participants (3.4%) randomised 
to the Orsiro BP- SES group and 203 of 5088 participants 
(4.0%) randomised to the DP- DES group. This was a 
statistically significant reduction in TVMI with BP- SES 
over DP- DES (OR 0.80; 95% CI 0.65 to 0.98; p=0.03). 
Other safety endpoints were not statistically different 
between the groups: Cardiac death (2.7% vs 2.9%; OR 
1.01 (95% CI 0.80 to 1.27); p=0.92), clinically driven TLR 
(4.5% vs 5.2%; OR 0.85 (95% CI 0.64 to 1.14); p=0.28) 
and ST (1.8% vs 2.2%; OR 0.87 (95% CI 0.55 to 1.37); 
p=0.54).
Meta-regression
There was no statistically significant interaction between 
ACS and treatment effect (TLF) at study level between the 
groups (OR=0.983 (per 10% increase in ACS) (95% CI 
0.898 to 1.077); p=0.626; figure 6)).
Sensitivity analyses and TSA
Our findings for both leave- one- out sensitivity anal-
yses and TSA are provided in the online supplemental 
appendix. Our sensitivity analysis showed that TLF 
remained significant after excluding BIOSCIENCE 
which reduced our pooled TLF by 10.4% (OR 0.773, 95% 
CI 0.646 to 0.926; p=0.005). Excluding any of the other 
studies resulted in an insignificant result between the two 
arms with the highest trend towards an increase in TLF 
of 7.1% after excluding BIOFLOW V (OR 0.912, 95% CI 
0.787 to 1.058; p=0.223). The TSA, however, suggested 
more trials are needed to achieve the required power for 
a conclusive meta- analysis.
DISCUSSION
In this meta- analysis of randomised trials comparing the 
Orsiro BP- SES and contemporary DP- DES, we found TLF 
to be significantly lower in participants randomised to 
the Orsiro BP- SES at a weighted average follow- up of 2.8 
years after PCI. There was a similar difference in TVMI 
but remaining clinical outcomes of cardiac mortality, 
clinically driven TLR and ST were similar between the 
two groups.
The most striking finding of reduction in TLF in 
favour of Orsiro BP- SES is noteworthy but requires 
careful consideration. Previous studies have reported 
similar directional trends without establishing statistical 
significance.6–8 However, the data from three recent 
trials (BIOSTEMI, BIOFLOW IV and BIOFLOW VI) 
and longer- term outcomes of trials (BIOFLOW II 5 years 
outcomes, BIOSCIENCE 5 years outcomes, BIO- RESORT 
3 years outcomes, BIOFLOW V 3 years outcomes, ORIENT 
3 years outcomes and BIONYX 2 years outcomes) together 
support a significant reduction in the odds of TLF for 
Orsiro BP- SES when compared with DP- DES (absolute 
risk reduction of 1.3%). This is driven predominantly 
by the significant reduction in TVMI in Orsiro BP- SES T
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patients as the remaining components of the composite 
index were similar between groups. This may relate to 
potential advantages of ultrathin strut stents in the treat-
ment of small vessel coronary artery disease (as suggested 
by subgroup analysis in BIO- RESORT) compared with its 
other attributes including the polymer location, degrada-
tion time of the polymer, the antiproliferation agent and 
the drug- elution kinetics.27
There are two possible stent factors which could 
explain our findings. The first and most pertinent stent 
factor that may explain reduction in TLF and TVMI is 
the ultrathin strut stent design of the ORSIRO stent. 
Both the DP- DES have thicker struts (XIENCE=81 µm 
and RESOLUTE=91 µm) compared with Orsiro BP- SES 
‘ultrathin’ strut (60 µm in stents <3.0 mm in diameter 
and >80 µm in stents >3.0 mm). Previous meta- analysis 
looking at all- comer ultrathin strut stents versus DP- DES 
have hinted at benefit in favour of the ultra- thin strut 
design.5 Thinner struts lead to greater flexibility and 
deliverability but crucially may be less traumatic to the 
endothelium and reduce perivascular inflammation 
promoting better endothelial coverage. Furthermore, 
they may be less likely to disturb flow in side branches 
and may decrease stent thrombogenicity with reduced 
detrimental low shear stress forces post deployment.28 29 
These beneficial effects of thinner struts are likely to be 
enhanced and more favourable in smaller vessels (BIO- 
RESORT- subgroup analysis).
Table 3 Odds ratios comparing clinical outcomes for Orsiro BP- SES and DP- DES
Orsiro BP- SES, % DP- DES, % OR 95% CI P value
Target lesion failure 8.2 9.5 0.82 0.69 to 0.98 0.03
Target vessel myocardial infarction 3.4 4.0 0.80 0.65 to 0.98 0.03
Cardiac mortality 2.7 2.9 1.01 0.80 to 1.27 0.92
Stent thrombosis 1.8 2.2 0.87 0.55 to 1.37 0.54
Clinically driven target lesion revascularisation 4.5 5.2 0.85 0.64 to 1.14 0.28
BP- SES, biodegradable polymer sirolimus- eluting stent; DP- DES, durable polymer drug- eluting stents.
Figure 3 Target lesion failure and secondary end points. 
BP- SES, biodegradable polymer sirolimus- eluting stent; DP- 
DES, durable polymer drug- eluting stents; TLR, target lesion 
revascularisation.
Figure 4 Forest plots of primary outcome (A) and 
secondary outcomes (B–E) for Orsiro BP- SES versus DP- 
DES. BP- SES, biodegradable polymer sirolimus- eluting stent; 
DP- DES, durable polymer drug- eluting stents.
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Second, the reduction in TLF seen may be attributable 
to the more biocompatible biodegradable polymer. The 
biodegradable polymer matrix of poly- L lactic acid in 
the Orsiro BP- SES degrades after 12–24 months. While 
previous meta- analyses included studies with shorter term 
follow- ups, our mean follow- up was 2.8 years and six out of 
the nine studies in our TLF analysis reported outcomes at 
24 months or more. This finding is novel and one provoc-
ative interpretation is reduction in TLF accrues related to 
better endothelialisation over the thinner struts assisted 
by polymer degradation.30 Concern about longer- term 
events with durable polymers are largely historical and 
were considered related to by- products of first generation 
DES polymer degradation implicated with immunoge-
nicity and vascular inflammation.9 Crucially, however, no 
superiority has been noted in other trials of non- ultrathin 
BP SES versus DP- DES.31
TVMI reflects reinfarction of the stented vessel 
including both peri- procedural myocardial infarction 
and spontaneous myocardial infarction. From the data 
presented, it was impossible to distinguish between these 
important types of myocardial infarction. Recent debate 
in the cardiovascular community32 has highlighted the 
importance of distinguishing between procedural and 
spontaneous MI and this may have helped us to charac-
terise further important differences between the groups. 
If the primary outcome difference was driven by peripro-
cedural events then this is less meaningful for patient 
care given that spontaneous myocardial infarcts are 
more strongly linked with major adverse cardiovascular 
events (including death) compared with periprocedural 
myocardial infarctions.33 It is most likely that the ultra-
thin design of the Orsiro BP- SES (<3 mm) contributed 
to reduced periprocedural MI via reduced side branch 
coverage, rather than the biodegradable polymer, to 
result in the reduced TVMI, the primary driver of the 
superior TLF.5 34
Subgroup analysis of participants with ACS did not show 
any significant effect on TLF which may relate to a lack of 
power from use of study- level rather than individual patient 
level data. ACS patients should be identified as a key 
research group of interest given the BIOSTEMI study and 
inferences from directional trend in our meta- regression . 
BIOSTEMI and the STEMI subgroup in BIOSCIENCE trial 
both had a stronger trend towards reduced TLF in ACS 
which could signal benefit of thinner struts in the setting of 
prothrombotic milieu.
Although all studies which reported TLF demonstrated 
a numerical trend towards a reduction in TLF, the finding 
was driven predominantly by one study (BIOFLOW V). 
Our results contrast with previous meta- analyses that 
show no difference in TLF, or any of the secondary 
outcomes, between the Orsiro BP- SES and DP- DES.6 8 
Our findings are, thus, novel and consistent with result of 
longer- term follow- up studies of Orsiro in addition to the 
recent BIOFLOW V trial.
Limitations
There are several limitations to this work. First, four of the 
trials had short 1- year follow- up. Whether the outcomes 
seen persist in the longer term after the complete degra-
dation of the polymer is unknown. Second, our meta- 
analysis was limited to aggregate study- level comparison 
which provides a less comprehensive comparison than 
patient- level data. The latter would have increased the 
power to detect interaction of treatment effect according 
to key subgroups (ACS or small vessels). Our meta- 
regression analysis did not show an effect signal for ACS 
but was underpowered to provide a definitive conclu-
sion on subgroups. A recent patient- level meta- analysis 
of four of the included trials (BIOFLOW II, BIOFLOW 
IV, BIOFLOW V and BIOSCIENCE) with 4480 patients 
showed a non- significant trend towards lower TLF in 
Figure 5 11 302 participants randomised across 9 RCTs 
between the Orsiro BP- SES and DP- DES groups showed 
a significant reduction in TLF in participants with the Orsiro 
BP- SES. BP- SES, biodegradable polymer sirolimus- eluting 
stent (Odds ratio 0.82; 95% CI 0.69-0.98; P=0.03); DP- DES, 
durable polymer drug- eluting stents; RCTs, randomised 
controlled trials; TLF, target lesion failure.
Figure 6 Interaction of ACS and treatment effect (TLF) at 
study level between BP- SES and DP- DES groups. ACS, 
acute coronary syndrome; BP- SES, biodegradable polymer 
sirolimus- eluting stent; DP- DES, durable polymer drug- 
eluting stents; TLF, target lesion failure.
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the Orsiro BP- SES.35 Third, it is important to note that 
the BIOSTEMI trial (n=1300) incorporated historical 
data of 407 patients with acute STEMI from the BIOSCI-
ENCE trial and these patients could not be excluded 
from analysis in both data sets. Fourth, while our study 
demonstrated low heterogeneity when comparing clin-
ical outcomes (I2=29%), there was lack of uniform data 
and reporting between the trials. Specifically, one study 
(PRISON IV) did not report TLF and our direct approach 
to the corresponding author for this information did not 
receive a response and hence this trial was not eligible 
forthe primary endpoint analysis. Fifth, although we 
performed a meta- regression on ACS status of partic-
ipants, clinical events were infrequent in all studies, 
and hence caution should be applied when comparing 
subgroups. Finally, the absolute difference is small, with 
large numbers of patients needed to treat. These may be 
offset by real life challenges of the ultra- thin strut stent 
platforms including limited radiographic visibility and 
reduced radial stregnth and maximum diameter stent 
expansion limits.
CONCLUSION
In this meta- analysis comparing modern generation 
DES platforms, patients randomly assigned to PCI with 
the ultrathin- strut biodegradable polymer stent (Orsiro) 
had reduced risk of target lesion failure compared 
with contemporary durable polymer DES with thicker 
stent struts at mean follow- up of 2.8 years. This benefit 
was largely driven by reduced target vessel myocardial 
infarction and supports the clinical utility of ultra- thin 
strut stent designs. Additional well powered randomised 
clinical trials with long- term follow- up are required to 
compare modern generation stent platforms focusing on 
different patient subgroups including small- vessel disease 
and acute coronary syndromes.
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